GUSELKUMAB TREATMENT MODULATES CORE PSORIATIC ARTHRITIS GENE EXPRESSION IN TWO PHASE 3 CLINICAL TRIALS (DISCOVER-1 AND-2)

被引：3
|
作者：
Siebert, S. [1 ]
Sweet, K. [2 ]
Ritchlin, C. T. [3 ]
Hsia, E. C. [2 ,4 ]
Kollmeier, A. [5 ]
Xu, X. L. [5 ]
Song, Q. [2 ]
Miron, M. [2 ]
机构：
[1] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland
[2] Janssen Res Dev LLC, Immunol, Spring House, PA USA
[3] Univ Rochester Med Ctr, Dept Med Allergy Immunol & Rheumatol SMD, Rochester, MN USA
[4] Univ Penn Med Ctr, Rheumatol, Philadelphia, PA USA
[5] Janssen Res Dev LLC, Immunol, San Diego, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
BIOLOGIC-NAIVE; DOUBLE-BLIND;
D O I：
10.1136/annrheumdis-2021-eular.479
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0195
引用
收藏
页码：312 / 312
页数：1
相关论文
共 50 条
  • [1] Guselkumab Treatment Modulates Core Psoriatic Arthritis Gene Expression in Two Phase 3 Clinical Trials (DISCOVER-1 and-2)
    Siebert, Stefan
    Sweet, Kristen
    Ritchlin, Christopher
    Hsia, Elizabeth
    Kollmeier, Alexa
    Xu, Xie
    Song, Qingxuan
    Miron, Michelle
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2795 - 2797
  • [2] Guselkumab treatment modulates genes differentially expressed in blood samples of patients with psoriatic arthritis vs healthy controls in two phase 3 clinical trials (DISCOVER-1 and-2)
    Siebert, Stefan
    Sweet, Kristen M.
    Ritchlin, Christopher T.
    Hsia, Elizabeth C.
    Kollmeier, Alexa P.
    Yang, Ya-Wen
    Xu, Xie L.
    Song, Qingxuan
    Miron, Michelle
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB170 - AB170
  • [3] Guselkumab, an anti-interleukin-23p19 monoclonal antibody, modulates core psoriatic arthritis gene expression in two phase III clinical trials (DISCOVER-1 and DISCOVER-2)
    Siebert, S.
    Sweet, K. M.
    Ritchlin, C. T.
    Hsia, E. C.
    Kollmeier, A. P.
    Xu, X. L.
    Song, Q.
    Miron, M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E14 - E15
  • [4] Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials
    Ritchlin, Christopher T.
    Rahman, Proton
    Helliwell, Philip S.
    Boehncke, Wolf-Henning
    McInnes, Iain
    Gottlieb, Alice B.
    Kollmeier, Alexa P.
    Shawi, May
    Zhou, Bei
    Mease, Philip J.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB151 - AB151
  • [5] Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and-2 Randomized Clinical Trials
    Mease, Philip
    Korotaeva, Tatiana
    Shesternya, Pavel
    Kokhan, Muza
    Rukavitsyn, Anton
    Vasilchenkov, Dmitry
    Sharaf, Mohamed
    Lavie, Frederic
    Deodhar, Atul
    [J]. RHEUMATOLOGY AND THERAPY, 2024,
  • [6] Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (DISCOVER-1 and DISCOVER-2)
    Siebert, Stefan
    McInnes, Iain
    Loza, Matthew J.
    Ma, Keying
    Leander, Karen
    Lakshminarayanan, Vani
    Franks, Carol
    Cooper, Philip
    Sweet, Kristen
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [7] GUSELKUMAB INDUCES SUSTAINED REDUCTION IN ACUTE PHASE PROTEINS AND TH17 EFFECTOR CYTOKINES IN ACTIVE PSORIATIC ARTHRITIS IN TWO PHASE-3 CLINICAL TRIALS (DISCOVER-1 AND DISCOVER-2)
    Siebert, S.
    Mcinnes, I.
    Loza, M. J.
    Ma, K.
    Leander, K.
    Lakshminarayanan, V.
    Franks, C.
    Cooper, P.
    Sweet, K.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 144 - 145
  • [8] Efficacy of guselkumab using composite endpoints in patients with active psoriatic arthritis: Domain-specific efficacy from DISCOVER-1 and DISCOVER-2 phase 3 trials
    Coates, Laura C.
    Ritchlin, Christopher T.
    Gossec, Laure
    Helliwell, Philip S.
    Rahman, Proton
    Kollmeier, Alexa P.
    Karyekar, Chetan
    Sheng, Shihong
    Agarwal, Prasheen
    Mease, Philip J.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB127 - AB127
  • [9] Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies
    Mease, Philip J.
    Helliwell, Philip S.
    Gladman, Dafna D.
    Poddubnyy, Denis
    Baraliakos, Xenofon
    Chakravarty, Soumya D.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Sweet, Kristen
    Shawi, May
    Karyekar, Chetan S.
    Deodhar, Atul
    van der Heijde, Desiree
    [J]. LANCET RHEUMATOLOGY, 2021, 3 (10): : E715 - E723
  • [10] Effects of guselkumab on musculoskeletal features in patients with active psoriatic arthritis by baseline skin disease: Results from the phase 3 DISCOVER-1 and DISCOVER-2 studies
    Gottlieb, Alice B.
    Mease, Philip
    Rahman, Proton
    Kollmeier, Alexa P.
    Zhou, Bei
    McInnes, Iain B.
    Deodhar, Atul
    Helliwell, Philip
    Ritchlin, Christopher T.
    Boehncke, Wolf-Henning
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB36 - AB36
12345